No­var­tis-backed Po­sei­da is pack­ing in the cash for its next-gen CAR-T work, adding a $110M ven­ture raise on top of its new­ly-re­filed IPO

A week af­ter up­dat­ing their S-1 in search of at least $115 mil­lion on the hot biotech IPO mar­ket, Po­sei­da Ther­a­peu­tics says it’s al­so raised a fresh ven­ture round — a lit­tle more than a year af­ter its last.

The first time around, af­ter Po­sei­da de­layed its IPO dur­ing a gov­ern­ment shut­down, the biotech re­port­ed a $150 mil­lion C round. This time around, it’s adding $110 mil­lion more from Fi­deli­ty Man­age­ment Re­search Com­pa­ny and oth­ers.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN